WallStSmart

Park Ha Biological Technology Co., Ltd. (BYAH)vsKimberly-Clark Corporation (KMB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Kimberly-Clark Corporation generates 655635% more annual revenue ($16.56B vs $2.52M). KMB leads profitability with a 12.8% profit margin vs 0.0%. KMB earns a higher WallStSmart Score of 58/100 (C).

BYAH

Avoid

30

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: -16.66

KMB

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 8.0Value: 4.0Quality: 4.0
Piotroski: 3/9Altman Z: 2.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BYAH.

KMBSignificantly Overvalued (-36.3%)

Margin of Safety

-36.3%

Fair Value

$78.97

Current Price

$99.04

$20.07 premium

UndervaluedFair: $78.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BYAH2 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

KMB1 strengths · Avg: 10.0/10
Return on EquityProfitability
118.0%10/10

Every $100 of equity generates 118 in profit

Areas to Watch

BYAH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.77M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

KMB4 concerns · Avg: 3.8/10
PEG RatioValuation
2.074/10

Expensive relative to growth rate

Price/BookValuation
18.3x4/10

Trading at 18.3x book value

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BYAH

The strongest argument for BYAH centers on Price/Book, Debt/Equity.

Bull Case : KMB

The strongest argument for KMB centers on Return on Equity.

Bear Case : BYAH

The primary concerns for BYAH are EPS Growth, Market Cap, Profit Margin.

Bear Case : KMB

The primary concerns for KMB are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 3.94 is elevated, increasing financial risk.

Key Dynamics to Monitor

KMB is growing revenue faster at 2.7% — sustainability is the question.

KMB generates stronger free cash flow (321M), providing more financial flexibility.

Monitor HOUSEHOLD & PERSONAL PRODUCTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

KMB scores higher overall (58/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Park Ha Biological Technology Co., Ltd.

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · China

Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company is headquartered in Wuxi, the People's Republic of China.

Kimberly-Clark Corporation

CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA

Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products. The company manufactures sanitary paper products and surgical & medical instruments. Kimberly-Clark brand name products include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper, Wypall utility wipes, KimWipes scientific cleaning wipes and Huggies disposable diapers and baby wipes.

Visit Website →

Want to dig deeper into these stocks?